Continuing Pharmacy Education / CE Master List / Law: People are not Cows and Off-label Prescribing is Utterly Different – RECORDED WEBINAR
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

Law: People are not Cows and Off-label Prescribing is Utterly Different – RECORDED WEBINAR

The Arthur E. Schwarting Symposium is an educational conference focused on pharmacy practice for pharmacists in many settings.

This year's sympoisum had an overall topic of Veterinary Medicines.

Learning Objectives

The activity met the following learning objectives for Pharmacists:
  • Discuss the characteristics and trends in off label prescribing.
  • Distinguish between off label prescribing for people and animals.
  • Describe the FDA’s authority to regulate off label prescribing

Activity Release Dates

Released:  April 25, 2024
Expires:  April 25, 2027

Course Fee

$17 Pharmacist

ACPE UAN Codes

 0009-0000-24-018-H03-P

Session Code

24RS18-ABC28

Accreditation Hours

1.0 hours of CE

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour  for completing the activity  (ACPE UAN 0009-0000-24-018-H03-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Gerald Gianutsos, PhD, JD
Professor Emeritus
University of Connecticut School of Pharmacy
Storrs, CT             

Faculty Disclosure

  • Gerry Gianutsos doesn't have any relationships with ineligible companies.

 

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Post Test Pharmacist

1. Off label drug uses generally do not become on-label uses. What is a primary reason for this?
A. There is a financial disincentive to manufacturers.
B. The FDA has no easy mechanism to accomplish this.
C. Manufacturers want to emphasize their drug’s primary.

2. You have a sick cow. Which of the following is correct about the type of drug that can be used for treatment?
A. Any drug approved by the FDA for human use.
B. A drug approved for use in chickens if there is no comparable drug approved for cows.
C. A drug that can be compounded by a pharmacist and added to the cow's feed.

3. What category of drugs has the highest rate of off-label use? (Prior to the pandemic.)
A. Anti-seizure drugs
B. Anti-depressants
C. Antibiotics
4. Why does the FDA take a hands-off approach to off-label use?
A. The FDA is not permitted to prevent manufacturers from touting an unapproved use once a drug has been approved.
B. The FDA does not regulate the practice of medicine.
C. The FDA can only act after it receives information of unintended consequences from off-label use.

5. When may a pharmacist recommend an OTC human drug for an animal?
A. Under any circumstances so long as it is not a food animal.
B. When there is no comparable veterinary product available.
C. A pharmacist may not recommend a human OTC drug for use in an animal.

6. Which of the following is a notable risk associated with illicit use of xylazine?
A. Naloxone-resistant overdose
B. Whole body rash and desquamation
C. Respiratory depression

7. The FDA was sued for publishing a warning about the off-label use of ivermectin for COVID. What was the basis of the lawsuit?
A. The FDA cannot prevent physicians from prescribing a drug off-label and need not issue warnings.
B. The FDA's warning on ivermectin was erroneous and used misplaced humor to try to sway opinions.
C. In publishing warning overstepped the FDA’s authority and interfered with the doctor-patient relationship.